PBF 680
Alternative Names: PBF-680Latest Information Update: 11 Mar 2025
At a glance
- Originator Palobiofarma
- Developer Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Palobiofarma
- Class Antiasthmatics
- Mechanism of Action Adenosine A1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Asthma
Highest Development Phases
- Phase II Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 07 Sep 2024 Efficacy and adverse event data from the phase II ADENOASMA trial in Asthma presented at the 34th Annual Congress of the European Respiratory Society (ERS-2024)
- 28 Jun 2022 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in Spain (PO, Capsule)
- 20 Dec 2021 Phase-II clinical trials in Chronic obstructive pulmonary disease in Spain (PO) (NCT05262218) (EudraCT2021-001732-25)